<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38436">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825122</url>
  </required_header>
  <id_info>
    <org_study_id>INVSC001</org_study_id>
    <nct_id>NCT01825122</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist, Nadolol, In Smoking Cessation of Patients With Pre-existing COPD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invion, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that 11-15 week treatment with the inverse agonist nadolol will
      improve smoking cessation in patients with COPD (chronic bronchitis dominant) compared to
      placebo and standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in the average number of cigarettes smoked per day in a week</measure>
    <time_frame>Last 28 days on study medication</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active, nadolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadolol</intervention_name>
    <arm_group_label>Active, nadolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Active cigarette-smoking males and females between the ages of 18-70 with documented
             physician-diagnosed COPD (chronic bronchitis dominant), as defined either by the
             American Thoracic Society or the World Health Organization.

          2. Desire to quit smoking in conjunction with participation in an approved smoking
             cessation program administered by the participating sites. Enrollment in the smoking
             cessation program must take place prior to Visit 3 (third dose escalation visit).

          3. Pre-bronchodilator FEV1 between 55 and 70% of predicted

          4. Baseline blood pressure ≥ 110/65mm Hg

          5. Baseline heart rate ≥ 60 beats/min.

          6. Smoking at least 10 cigarettes per day prior to participation in the approved smoking
             cessation program.

          7. Previous failure to quit smoking due to:

               -  cough/ and or sputum, and/ or

               -  sleep disturbance due to increased cough

          8. Able to complete diary cards and comply with study procedures.

          9. Females of childbearing age may participate only if they have a negative pregnancy
             test, are non-lactating, and agree to practice an adequate birth control method
             (abstinence, combination barrier and spermicide, or hormonal) for the duration of the
             study.

        Exclusion Criteria:

        Subjects who meet ANY of the following criteria are not eligible for enrollment:

          1. Diagnosis of asthma, cystic fibrosis, or PiZZ emphysema

          2. Inability or unwillingness to give written informed consent

          3. History of upper/lower respiratory tract infection, COPD exacerbation requiring
             systemic steroids, antibiotics, and or ER visit or urgent care within 6 weeks of
             Visit 1

          4. History of adverse reaction or allergy to nadolol

          5. History of neurological, hepatic, renal, or other medical conditions that may
             interfere with the interpretation of data or the patient's participation in the study
             or may increase safety concerns

          6. History of cardiovascular diseases including uncontrolled hypertension (BP &gt;160/100),
             ischemic heart disease, congestive heart failure (NYHA III or IV), valvular heart
             disease or cardiomyopathy

          7. Known allergy or sensitivity to atropine or ipratropium bromide

          8. Documented or self-reported current history of alcoholism or drug abuse

          9. Participation in another research trial within 30 days of starting this trial

         10. Unwillingness or inability to comply with study procedures

         11. Inability to swallow the study medication capsule

         12. Pregnant or nursing

         13. Current use of any other beta-blocker medication, Verapamil or diltiazem
             (non-dihydropyridine calcium channel blockers), OTC remedies containing
             pseudoephedrine, ephedrine-based or containing dietary or herbal supplements, and or
             ACE inhibitors.

         14. Scheduled for surgery requiring general anaesthesia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Castro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University of St. Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cornelius Pitts, Pharm.D</last_name>
    <phone>215-518-0466</phone>
    <email>cornelius.pitts@inviongroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Ksiazek</last_name>
      <email>DKsiazek@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Mario Castro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Smoking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nadolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
